A Phase 1/2 Study Of KW-2478, An Hsp 90 Inhibitor, In Combination With Bortezomib (BTZ) In Patients (Pts) With Relapsed/Refractory (R/R) Multiple Myeloma (MM)
Jamie, Cavanagh, Baylon, Honorata Giongco, Caguioa, Priscilla B., Davies, Faith E., Gharibo, Mecide, Akinaga, Shiro, Kurman, Michael R., Novak, Barbara A., Yong, Kwee L.
Published in Blood (15.11.2013)
Published in Blood (15.11.2013)
Get full text
Journal Article